Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20482939 | 0.85 | MEN1 (0.39) | MEN1KMT2ATTRALBCA2 | |
| SCHEMBL1232210 | 0.84 | MEN1 (0.47) | MEN1KMT2ATTRALBCA2 | |
| SCHEMBL1232330 | 0.82 | MEN1 (0.39) | MEN1KMT2ATTRALBCA2 | |
| SCHEMBL595139 | 0.81 | PARP15 (0.44) | MEN1KMT2ACYP19A1 | |
| SCHEMBL13608787 | 0.81 | CA2 (0.41) | MEN1KMT2ACA2CA12CA3 | |
| SCHEMBL27528549 | 0.80 | LOXL2 (0.47) | MEN1KMT2ATTRALBCA2 | |
| SCHEMBL2934457 | 0.80 | CYP2A6 (0.47) | MEN1KMT2ATTRALBGSK3B | |
| SCHEMBL27455430 | 0.78 | GSK3B (0.39) | MEN1KMT2ATTRALBGSK3B | |
| SCHEMBL6214320 | 0.78 | KLF10 (0.46) | MEN1KMT2ACA2CA12CA3 | |
| SCHEMBL16961104 | 0.78 | CA2 (0.38) | MEN1KMT2ACA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010622-B | Preparation method of 2-bromo-5-cyanobenzaldehyde | 山东百启生物医药有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-115010622-A | Preparation method of 2-bromo-5-cyanobenzaldehyde | 山东百启生物医药有限公司 | 2022-09-06 | — | — | CN | claimed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-115010622-B | Preparation method of 2-bromo-5-cyanobenzaldehyde | 山东百启生物医药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| CN-115010622-A | Preparation method of 2-bromo-5-cyanobenzaldehyde | 山东百启生物医药有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20220089525-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-24 | — | — | US | disclosed |
| EP-3971191-A1 | BORON-CONTAINING SMALL MOLECULES | Bill And Melinda Gates Foundation (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3915638-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-12-01 | — | — | EP | disclosed |
| WO-2007146965-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293457-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007131072-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007095638-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007078340-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060234981-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234981-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | MEN1 522/4885KMT2A 2353/4885TTR 3133/4885 |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | MEN1 4629/4885KMT2A 4096/4885TTR 1784/4885 |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | MEN1 3979/4885KMT2A 4553/4885TTR 3794/4885 |
| US-20220089525-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2B, GRIN2A | MEN1 675/4885KMT2A 1193/4885TTR 3592/4885 |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | MEN1 3979/4885KMT2A 4553/4885TTR 3794/4885 |
| US-20070293457-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, TNF | MEN1 4264/4885KMT2A 4406/4885TTR 3590/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | MEN1 522/4885KMT2A 2353/4885TTR 3133/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | MEN1 1063/4885KMT2A 625/4885TTR 3470/4885 |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | MEN1 663/4885KMT2A 2279/4885TTR 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.